Regulated in Pancreatic Cancer Chronic Pancreatitis Identifies Multiple Genes Differentially Molecular Profiling of Pancreatic Adenocarcinoma and Updated

The molecular basis of pancreatic cancer is not understood. Previous attempts to determine the specific genes expressed in pancreatic cancer have been hampered by similarities between adenocarcinoma and chronic pancreatitis. In the current study, microarrays (Affymetrix) were used to profile gene expression in pancreatic adenocarcinoma (10), pancreatic cancer cell lines (7), chronic pancreatitis (5), and normal pancreas (5). Molecular profiling indicated a large number of genes differentially expressed between pancreatic cancer and normal pancreas but many fewer differences between pancreatic cancer and chronic pancreatitis, likely because of the shared stromal influences in the two diseases. To specifically identify genes expressed in neoplastic epithelium, we selected genes more highly expressed (>2-fold, p < 0.01) in adenocarcinoma compared with both normal pancreas and chronic pancreatitis and which were also highly expressed in pancreatic cancer cell lines. This strategy yielded 158 genes, of which 124 were not previously associated with pancreatic cancer. Quantitative-reverse transcription-PCR for two molecules, S100P and 14-3-3 , validated the microarray data. Support for the success of the neoplastic cell gene expression identification strategy was obtained by immunocytochemical localization of four representative genes, 14-3-3 , S100P, S100A6, and 4 integrin, to neoplastic cells in pancreatic tumors. Thus, comparisons between pancreatic adenocarcinoma, pancreatic cancer cell lines, normal pancreas, and chronic pancreatitis have identified genes that are selectively expressed in the neoplastic epithelium of pancreatic adenocarcinoma. These data provide new insights into the molecular pathology of pancreatic cancer that may be useful for detection, diagnosis, and treatment.

[1]  Rork Kuick,et al.  Molecular profiling of pancreatic adenocarcinoma and chronic pancreatitis identifies multiple genes differentially regulated in pancreatic cancer. , 2003, Cancer research.

[2]  Carlo Giussani,et al.  Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo. , 2003, Cancer research.

[3]  Y. Atomi,et al.  Diagnostic Significance of High Mobility Group I(Y) Protein Expression in Intraductal Papillary Mucinous Tumors of the Pancreas , 2002, Pancreas.

[4]  Tatjana Crnogorac-Jurcevic,et al.  Expression profiling of microdissected pancreatic adenocarcinomas , 2002, Oncogene.

[5]  Haiyong Han,et al.  Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. , 2002, Cancer research.

[6]  Kimberly Walter,et al.  Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. , 2002, The American journal of pathology.

[7]  Giovanni Parmigiani,et al.  Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. , 2002, Cancer research.

[8]  J. Cameron,et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  Tatjana Crnogorac-Jurcevic,et al.  Gene expression profiles of pancreatic cancer and stromal desmoplasia , 2001, Oncogene.

[10]  G Rennert,et al.  Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. , 2001, The American journal of pathology.

[11]  E. Castaños-Vélez,et al.  Immunohistochemical expression of extracellular matrix proteins and adhesion molecules in pancreatic carcinoma. , 2001, Hepato-gastroenterology.

[12]  U. Weidle,et al.  Transcriptional profiling of cell lines derived from an orthotopic pancreatic tumor model reveals metastasis-associated genes. , 2001, Anticancer research.

[13]  A. Bosserhoff,et al.  Isolation of invasion-associated cDNAs in melanoma , 2001, Archives of Dermatological Research.

[14]  W. Jonat,et al.  Expression of the tumor suppressor gene Maspin in human pancreatic cancers. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[15]  R H Hruban,et al.  Invasion-specific genes in malignancy: serial analysis of gene expression comparisons of primary and passaged cancers. , 2001, Cancer research.

[16]  D. Lockhart,et al.  Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[17]  Andrea Califano,et al.  Analysis of Gene Expression Microarrays for Phenotype Classification , 2000, ISMB.

[18]  M Dietel,et al.  Increased expression of epidermal fatty acid binding protein, cofilin, and 14‐3‐3‐σ (stratifin) detected by two‐dimensional gel electrophoresis, mass spectrometry and microsequencing of drug‐resistant human adenocarcinoma of the pancreas , 1999, Electrophoresis.

[19]  D. Botstein,et al.  Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[20]  K. Kinzler,et al.  Identifying markers for pancreatic cancer by gene expression analysis. , 1998, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[21]  M. Talamini,et al.  Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s: pathology, complications, and outcomes. , 1997, Annals of surgery.

[22]  S. Zeuzem,et al.  Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer. , 1997, Anticancer research.

[23]  H. Friess,et al.  Identification of genes with specific expression in pancreatic cancer by cDNA representational difference analysis , 1997, Genes, chromosomes & cancer.

[24]  H. Friess,et al.  A pancreatic cancer-specific expression profile. , 1996, Oncogene.

[25]  M. Löhr,et al.  Expression and Function of Receptors for Extracellular Matrix Proteins in Human Ductal Adenocarcinomas of the Pancreas , 1996, Pancreas.

[26]  H. Mannherz,et al.  Monoclonal antibodies against 5'-nucleotidase from a human pancreatic tumor cell line: their characterization and inhibitory capacity on tumor cell adhesion to fibronectin substratum. , 1992, European Journal of Cell Biology.

[27]  R. Bresalier,et al.  Characterization of the Cytokeratins of Human Colonic, Pancreatic, and Gastric Adenocarcinoma Cell Lines , 1992, Pancreas.

[28]  J. Cameron,et al.  Overexpression of S100A4 in pancreatic ductal adenocarcinomas is associated with poor differentiation and DNA hypomethylation. , 2002, The American journal of pathology.

[29]  Irving Waxman,et al.  A multispecialty approach to the diagnosis and management of pancreatic cancer , 2000, American Journal of Gastroenterology.

[30]  J. Hoheisel,et al.  Isolation of Differentially Expressed Genes by Combining Representational Difference Analysis ( RDA ) and cDNA Library Arrays , 1999 .

[31]  R H Hruban,et al.  Gene expression profiles in normal and cancer cells. , 1997, Science.